Skip to main content

Table 1 Estimated effect size for respiratory outcome (wheeze at any time during first year of life) for anticipated questionnaire returns

From: Follow-up study of infants recruited to the randomised, placebo-controlled trial of azithromycin for the prevention of chronic lung disease of prematurity in preterm infants—study protocol for the AZTEC-FU study

Size per group

Prevalence of wheezing after treatment

Detectable effect size

Power 0.8, alpha 0.05, initial incidence of wheeze 65%

 350

54.3%

10.7%

 300

53.5%

11.5%

 250

52.3%

12.7%

 200

50.7%

14.3%

Power 0.9, alpha 0.05, initial incidence of wheeze 65%

 350

52.7%

12.3%

 300

51.7%

13.3%

 250

50.4%

14.6%

 200

48.5%

16.5%